Clinical Study Confirms Safety and Efficacy of Novel Germicidal Device to Help Prevent Hospital-Acquired Infections
Posted on: Wednesday, 22 February 2006, 21:00 CST
BOSTON, Feb. 22 /PRNewswire/ -- Catheter site infections are among the most common and serious hospital-acquired infections. UVSolutions (http://www.uvs-ultraclean.com/) announces that data from a recently completed clinical study confirms its patented catheter site disinfection system (also patented for wound care) is safe and efficacious on the most sensitive skin.
*(PHOTO: Send2Press.com/mediadesk/0206-UVS-Disinfector_72dpi.jpg) *(Photo Caption: Catheter Site Disinfection System.)
Hospital-acquired (nosocomial) infections affect 1 in 20 patients and kill more people than car accidents and homicides combined. The CDC estimated that in the U.S. in 1995, nosocomial infections cost $4.5 billion and contributed to more than 88,000 deaths -- one death every 6 minutes. And, of the CDC's 7 Healthcare Safety Challenges, the first is to "Reduce catheter-associated adverse events by 50% among patients in a healthcare setting."
Catheters routinely provide hospitalized patients with medication, nutrition, hydration etc. The largest single cause of catheter related infections is colonization of microorganisms around the catheter entry site, under the dressing. The microorganisms multiply and migrate down the outside of the catheter into the blood stream, causing blood stream infections (BSI's). UVSolutions has developed a novel system to significantly reduce colonization of microorganisms around the catheter site. The disinfection system includes a palm-sized, battery operated, germicidal ultraviolet device placed over the catheter site to instantly deliver a single flash of UVC light through a proprietary dressing. UVSolutions seeks to partner with market leaders to commercialize the catheter site disinfection system and the wound care system.
"UVSolutions' proprietary Catheter Site Disinfection System is instant and painless. This novel disinfection system will help prevent the buildup of microorganisms around the catheter site that cause infections with a single dose of germicidal UV light per day. The longer a patient requires catheterization, the higher the risk of infection. And, germicidal UVC does not contribute to the development of resistant strains of microorganisms, as do other antimicrobials and antibiotics," reports Sandra Kimball, President of the Boston-based company.
UVSolutions' medical infection control products provide revolutionary low-cost, non-chemical sterilization and disinfection solutions to help reduce escalating incidences and costs associated with nosocomial infections.
UVSolutions' consumer products provide families with low cost, non-chemical, antimicrobial personal care and water purification products in the wake of increasing demand for infection control products.
UVSolutions LLC is a privately held product development company in Boston, Massachusetts. The Company licenses its proprietary products to market leaders. Other products under development include a stethoscope disinfector and rapid germicidal water purification products for home, travel and personal use. UVSolutions holds a portfolio of patents including the issued "Gatekeeper" patent for catheter and wound site disinfection.
More information: http://www.uvs-ultraclean.com/
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.send2press.com/
UVSolutions LLC
CONTACT: Media, Sandra Kimball, President of UVSolutions LLC,+1-617-375-0285, sandrakimball@uvs-ultraclean.com; or plain text copy:http://send2press.com/mediadrome/2006-02-022-005.txt
Web site: http://www.uvs-ultraclean.com/
Source: PRNewswire
Related Articles
- Reportlinker Adds US Infection Prevention Products & Services Report
- Banking Experts Offer Educational Web Site at www.TheRatingsDebate.com to Outline Ways to Improve Credit Ratings System for Structured Products
- MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
- Lockheed Martin Prepares Australia's First Aegis Weapon System For Post-Production Testing
- Toshiba Strata CIX Family of VoIP Systems Wins Network Products Guide Reader Trust Award for 2008 Best VoIP Product
- NovaBay Pharmaceuticals Commences Phase I Human Clinical Trial for the Prevention of Catheter Associated Urinary Tract Infections
- NovaBay Pharmaceutical's Investigational New Drug Application (IND) for the Prevention of Catheter Associated Urinary Tract Infections Cleared By FDA
- US Demand for Infection Prevention Products &Amp; Services to Reach $16.8 Billion in 2011
- Avectra Announces netFORUM On-Site Registration System
- Record Fourth Quarter Sales and Orders Of Viraguard(R) Infection Control Products Projected; Sales and Orders for Q4 Already Exceed $410,000
User Comments (0)

RSS Feeds